

# Ryan A Wilcox

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5468202/publications.pdf>

Version: 2024-02-01

61  
papers

3,226  
citations

236925

25  
h-index

155660

55  
g-index

61  
all docs

61  
docs citations

61  
times ranked

4147  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. <i>Blood</i> , 2014, 123, 2915-2923.	1.4	435
2	Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1192-1204.	10.7	398
3	B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. <i>Blood</i> , 2009, 114, 2149-2158.	1.4	202
4	Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. <i>Lancet Haematology</i> , the, 2019, 6, e630-e637.	4.6	194
5	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. <i>Blood</i> , 2019, 133, 1664-1676.	1.4	184
6	GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. <i>Blood</i> , 2014, 123, 3007-3015.	1.4	158
7	Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. <i>Blood</i> , 2009, 114, 2936-2944.	1.4	144
8	Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2016, 91, 151-165.	4.1	118
9	Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2017, 92, 1085-1102.	4.1	104
10	A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. <i>Blood</i> , 2014, 124, 3768-3771.	1.4	90
11	The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 575-580.	1.3	79
12	Mycosis fungoides and S�azary syndrome: 2019 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2019, 94, 1027-1041.	4.1	77
13	Cancer-Associated Myeloproliferation: Old Association, New Therapeutic Target. <i>Mayo Clinic Proceedings</i> , 2010, 85, 656-663.	3.0	71
14	A three-signal model of T-cell lymphoma pathogenesis. <i>American Journal of Hematology</i> , 2016, 91, 113-122.	4.1	64
15	Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?. <i>Blood Reviews</i> , 2016, 30, 89-100.	5.7	63
16	Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2011, 86, 928-948.	4.1	61
17	Cutaneous T-cell lymphoma: 2014 Update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2014, 89, 837-851.	4.1	58
18	T-cell Receptor Signaling Activates an ITK/NF-�B/GATA-3 axis in T-cell Lymphomas Facilitating Resistance to Chemotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 2506-2515.	7.0	49

#	ARTICLE	IF	CITATIONS
19	Cutaneous Bâ€cell lymphomas: 2019 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2018, 93, 1427-1430.	4.1	49
20	Mogamulizumab: 2 birds, 1 stone. Blood, 2015, 125, 1847-1848.	1.4	42
21	Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2016, 22, 6118-6128.	7.0	42
22	A retrospective comparative outcome analysis following systemic therapy in <scp>M</scp>ycosis fungoides and <scp>S</scp>ezary syndrome. American Journal of Hematology, 2016, 91, E491-E495.	4.1	41
23	Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability. Clinical Cancer Research, 2020, 26, 690-703.	7.0	41
24	Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma. Cancers, 2020, 12, 2311.	3.7	38
25	Cutaneous Bâ€cell lymphomas: 2015 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2015, 90, 73-76.	4.1	35
26	A new molecular paradigm in mycosis fungoides and SÃ©zary syndrome. Seminars in Diagnostic Pathology, 2017, 34, 15-21.	1.5	25
27	Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents. American Journal of Clinical Dermatology, 2016, 17, 225-237.	6.7	24
28	Cutaneous <scp>B</scp>â€cell lymphomas: 2016 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2016, 91, 1052-1055.	4.1	22
29	Cutaneous Bâ€cell lymphomas: 2013 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2013, 88, 73-76.	4.1	21
30	Pyrimidine tract-binding protein 1 mediates pyruvate kinase M2-dependent phosphorylation of signal transducer and activator of transcription 3 and oncogenesis in anaplastic large cell lymphoma. Laboratory Investigation, 2017, 97, 962-970.	3.7	21
31	A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral Tâ€cell lymphomas. American Journal of Hematology, 2017, 92, 1287-1294.	4.1	21
32	Cutaneous Bâ€cell lymphomas: 2021 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2020, 95, 1209-1213.	4.1	21
33	Cutaneous Tâ€cell lymphomas: 2021 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2021, 96, 1313-1328.	4.1	21
34	Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multiâ€institutional study. American Journal of Hematology, 2016, 91, 687-691.	4.1	20
35	Survival following salvage therapy for primary refractory peripheral Tâ€cell lymphomas (PTCL). American Journal of Hematology, 2018, 93, 394-400.	4.1	19
36	Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders. , 2016, 4, 95.		18

#	ARTICLE	IF	CITATIONS
37	The B7 Homologues and their Receptors in Hematologic Malignancies. <i>European Journal of Haematology</i> , 2012, 88, 465-475.	2.2	17
38	Survival in patients with limited-stage peripheral T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2015, 56, 1665-1670.	1.3	16
39	Expression of the checkpoint receptors LAG-3, TIM-3 and VISTA in peripheral T cell lymphomas. <i>Journal of Clinical Pathology</i> , 2020, 73, 197-203.	2.0	16
40	The role of aurora A and polo-like kinases in high-risk lymphomas. <i>Blood Advances</i> , 2019, 3, 1778-1787.	5.2	15
41	Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas. <i>Oncotarget</i> , 2017, 8, 114474-114480.	1.8	15
42	GATA-3 in T-cell lymphoproliferative disorders. <i>IUBMB Life</i> , 2020, 72, 170-177.	3.4	11
43	Ruxolitinib in adult patients with secondary hemophagocytic lymphohistiocytosis. <i>American Journal of Hematology</i> , 2021, 96, E103-E105.	4.1	9
44	Optimising initial treatment for peripheral T-cell lymphoma: a tough nut to CHOP. <i>Lancet Haematology</i> , 2018, 5, e182-e183.	4.6	6
45	Janus Family kinase (JAK) inhibitors in HLH and severe COVID-19. <i>American Journal of Hematology</i> , 2020, 95, 1448-1451.	4.1	6
46	Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 8003-8014.	2.0	5
47	Germline variants discovered in lymphoma patients undergoing tumor profiling: a case series. <i>Familial Cancer</i> , 2021, 20, 61-65.	1.9	5
48	Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multicenter analysis. <i>Hematological Oncology</i> , 2021, 39, 473-482.	1.7	5
49	Patch/plaque mycosis fungoides-like presentations of DUSP22-translocated T-cell lymphomas. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 299-305.	1.3	5
50	ECP in the spotLIGHT. <i>Blood</i> , 2019, 134, 1275-1277.	1.4	4
51	Distinguishing reactive inflammatory dermatoses from lymphoma: 2 cases of severe drug reactions to phenytoin/phenobarbital and rosuvastatin mimicking lymphoma. <i>JAAD Case Reports</i> , 2020, 6, 311-315.	0.8	4
52	Novel therapies targeting cutaneous T cell lymphomas and their microenvironment. <i>Seminars in Hematology</i> , 2021, 58, 103-113.	3.4	4
53	Effect of early endometriosis on ovarian reserve and reproductive outcome. <i>Frontiers in Bioscience - Scholar</i> , 2015, 7, 40-45.	2.1	4
54	A unique three-way Philadelphia chromosome variant t(4;9;22)(q21;q34;q11.2) in a newly diagnosed patient with chronic phase chronic myeloid leukemia: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2021, 15, 285.	0.8	3

#	ARTICLE	IF	CITATIONS
55	Spontaneous Regression of High-Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements: Case Report and Literature Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e120-e125.	0.4	2
56	Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-9.	1.3	2
57	A survey of the therapeutic landscape in peripheral T-cell lymphomas: the importance of expert hematopathology review in the era of targeted therapies and precision medicine. <i>Annals of Lymphoma</i> , 2019, 3, 9-9.	4.5	1
58	Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways. <i>Blood</i> , 2016, 128, 4096-4096.	1.4	1
59	Inhibition of IL2-Inducible T-Cell Kinase (ITK)-Mediated Chemoresistance By Ibrutinib in T-Cell Lymphoproliferative Disorders. <i>Blood</i> , 2015, 126, 1467-1467.	1.4	0
60	Getting ALK inhibitors SHPshape. <i>Blood</i> , 2022, 139, 642-643.	1.4	0
61	A real-world experience: Outcomes among relapsed/refractory diffuse large B cell lymphoma patients with CD20 loss.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19570-e19570.	1.6	0